Cite
HARVARD Citation
Powles, T. et al. (2020). Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet oncology. 21 (12), pp. 1574-1588. [Online].